Ro vs Amazon One Medical
Two GLP-1 desks, one scoreboard. We put Ro and Amazon One Medical head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
Amazon One Medical
The verdict
Ro takes this head-to-head.
Ro scores 87 to 86 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make Amazon One Medical a bad call — it's best for readers who want a trusted, deep-pocketed brand and brand-name access over a published flat compounded price. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Ro | Amazon One Medical | |
|---|---|---|
| Brief Score | 87/100 (B+) | 86/100 (B) |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | Multi-state | All 50 states |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Stableprice stable | Stableprice stable |
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
Amazon One Medical: Brand-access model through One Medical clinicians; compounded pricing isn't published, so there's no sticker to track.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.